课题基金 / 基金详情

Identification of compounds that activate interferon to treat viral infections

Identification of compounds that activate interferon to treat viral infections
鉴定激活干扰素以治疗病毒感染的化合物
批准号:
8181991
负责人:
Luis Martinez-Sobrido
金额:
$15.45万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2013-06-30

项目摘要

项目成果

Luis Martinez-Sobrido的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):先天免疫反应是抵抗病毒感染的第一道屏障,并提供发展适当免疫反应所需的初始信号。干扰素(IFN)是先天免疫系统的重要组成部分,是目前治疗广泛病毒感染的有效药物。然而,对于没有疫苗的高致病性病毒或对病毒抑制剂具有耐药性的病毒株,特别需要新的抗病毒药物。由于干扰素反应诱导细胞抗病毒状态,阻止病毒复制,诱导和/或激活干扰素反应的化合物将成为治疗病毒感染的令人兴奋的候选药物。本应用旨在鉴定干扰素诱导的小分子化合物,用于治疗广谱病毒感染和其他干扰素相关的人类疾病。这些干扰素诱导化合物也可用作病毒疫苗的免疫调节剂和/或佐剂,说明它们对人类健康的直接和重大影响。我们将使用一种新颖、简单、灵敏的基于细胞的检测方法来鉴定诱导和/或激活先天免疫反应的化合物。为了实现这一目标,我们将:开发和调整一种基于细胞的检测方法,以识别诱导和/或激活先天免疫反应的化合物(目标1)。具体来说,我们将筛选两个结构多样的小分子化合物文库,以证明我们基于细胞的检测方法转化为自动化高通量筛选(HTS)格式的可行性。接下来,我们将使用二次分析来验证已识别的命中及其生物学相关性(目标2)。我们将通过二级分析证明在一级筛选中有活性的化合物为阳性,评估其物种特异性、作用机制和毒性,以便在抗病毒测试中优先确定其特征。我们直接的基于细胞的检测代表了一种全面可靠的方法,可以立即识别有希望的IFN调节剂,以治疗依赖IFN独特使用的病毒感染和其他人类疾病。这个项目将使我们能够实现我们的长期目标,即在临床前动物模型中展示所鉴定化合物的抗病毒特性,以选择主要的治疗候选药物。
英文摘要
DESCRIPTION (provided by applicant): The innate immune response represents the first barrier against viral infections and provides the initial signal required for development of an appropriate immune response. Interferon (IFN) constitutes a critical element of the innate immune system and is a current therapeutic agent that is effective against a broad spectrum of viral infections. However, new antiviral drugs are particularly needed for highly pathogenic viruses for which no vaccine is available or for virus strains resistant to viral inhibitors. Because the IFN response induces a cellular antiviral state that prevents virus replication, compounds that induce and/or activate the Interferon response will represent exciting candidates as therapeutics to treat viral infections. This application aims to identify interferon-inducing small molecule compounds for the treatment of a broad spectrum of viral infections and other interferon-related human diseases. These interferon-inducing compounds could be also used as immunomodulators and/or adjuvants for viral vaccines, illustrating their immediate and significant impact on human health. We will use a novel, simple, and sensitive cell-based assay to identify compounds that induce and/or activate the innate immune response. To achieve this, we will: develop and adapt a cell-based assay to identify compounds that induce and/or activate the innate immune response (Aim 1). Specifically, we will screen two libraries of structurally diverse small molecule compounds to demonstrate the feasibility of our cell-based assay to be translated to automated high-throughput screening (HTS) format. Next, we will use secondary assays to validate identified hits and their biological relevance (Aim 2). We will certify the compounds active in the primary screen as positive hits by secondary assays, evaluating their species specificity, mechanism of action and toxicity in order to prioritize their characterization in antiviral assays. Our straightforward cell-based assay represents a comprehensive and reliable approach for the immediate identification of promising IFN modulators to treat viral infections and other human diseases that rely on the unique use of IFN. This project will allow us to reach our long term goals of demonstrating the antiviral properties of the identified compounds in preclinical animal models to select lead therapeutic candidates. PUBLIC HEALTH RELEVANCE: There is a great need for new antiviral drugs, particularly against highly pathogenic viruses for which no vaccine is yet available or virus strains that become resistant to viral inhibitors. Because the interferon (IFN) response induces an antiviral state in cells that prevents virus replication, compounds that enhance or activate the IFN response represent lead candidates as antivirals, vaccine adjuvants, or potential immunomodulators. Using our high throughput cell-based assay, we will identify IFN-modulating compounds that will represent promising therapeutics to treat viral infections and other human diseases that rely on the unique use of IFN.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Attenuation of Lassa Virus Via Codon Deoptimization
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus Biology
  • 批准号:
    9901456
  • 项目类别:
  • 资助金额:
    $43.44万
  • 财政年份:
    2019
  • 负责人:
    Luis Martinez-Sobrido
  • 依托单位:
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus Biology
  • 批准号:
    10395433
  • 项目类别:
  • 资助金额:
    $43.44万
  • 财政年份:
    2019
  • 负责人:
    Luis Martinez-Sobrido
  • 依托单位:
Roles of the Nucleoprotein 3'-5' Exonuclease Domain in Arenavirus Biology
  • 批准号:
    9765080
  • 项目类别:
  • 资助金额:
    $45.78万
  • 财政年份:
    2019
  • 负责人:
    Luis Martinez-Sobrido
  • 依托单位:
海外基金